324 related articles for article (PubMed ID: 19793318)
21. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer.
Bianchi SD; Scoletta M; Cassione FB; Migliaretti G; Mozzati M
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug; 104(2):249-58. PubMed ID: 17560140
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment.
Fehm T; Felsenberg D; Krimmel M; Solomayer E; Wallwiener D; Hadjii P
Breast; 2009 Aug; 18(4):213-7. PubMed ID: 19651512
[TBL] [Abstract][Full Text] [Related]
23. [Bisphosphonates and osteonecrosis of the jaws].
Urade M
Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
[TBL] [Abstract][Full Text] [Related]
24. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
[TBL] [Abstract][Full Text] [Related]
25. A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer.
Goldman ML; Denduluri N; Berman AW; Sausville R; Guadagnini JP; Kleiner DE; Brahim JS; Swain SM
Oncology; 2006; 71(3-4):306-8. PubMed ID: 17657174
[TBL] [Abstract][Full Text] [Related]
26. Multiple osteonecrosis of the jaw, oral bisphosphonate therapy and refractory rheumatoid arthritis (Pathological fracture associated with ONJ and BP use for osteoporosis).
Grana J; Mahia IV; Meizoso MO; Vazquez T
Clin Exp Rheumatol; 2008; 26(2):384-5. PubMed ID: 18565271
[No Abstract] [Full Text] [Related]
27. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series.
Freiberger JJ; Padilla-Burgos R; Chhoeu AH; Kraft KH; Boneta O; Moon RE; Piantadosi CA
J Oral Maxillofac Surg; 2007 Jul; 65(7):1321-7. PubMed ID: 17577496
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
29. Biophosphonate-related osteonecrosis of the jaws.
Ruggiero SL; Woo SB
Dent Clin North Am; 2008 Jan; 52(1):111-28, ix. PubMed ID: 18154867
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonate-related osteonecrosis of the jaw in cancer patients: Implications for nurses.
Morris M; Cruickshank S
Eur J Oncol Nurs; 2010 Jul; 14(3):205-10. PubMed ID: 20129822
[TBL] [Abstract][Full Text] [Related]
31. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition.
Melo MD; Obeid G
J Am Dent Assoc; 2005 Dec; 136(12):1675-81. PubMed ID: 16383049
[TBL] [Abstract][Full Text] [Related]
32. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
[TBL] [Abstract][Full Text] [Related]
33. [Osteonecrosis of the jaw developing during bisphosphonate treatment].
Udvardy E; Redl P; Márton I
Magy Onkol; 2008 Mar; 52(1):81-7. PubMed ID: 18403302
[TBL] [Abstract][Full Text] [Related]
34. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Nastro E; Musolino C; Allegra A; Oteri G; Cicciù M; Alonci A; Quartarone E; Alati C; De Ponte FS
Acta Haematol; 2007; 117(3):181-7. PubMed ID: 17164581
[TBL] [Abstract][Full Text] [Related]
35. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonates and osteonecrosis of the jaw: proceedings of an international conference.
Bilezikian JP; Grbic JT
Ann N Y Acad Sci; 2011 Feb; 1218():1-2. PubMed ID: 21291476
[TBL] [Abstract][Full Text] [Related]
37. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?
Reid IR; Bolland MJ; Grey AB
Bone; 2007 Sep; 41(3):318-20. PubMed ID: 17572168
[TBL] [Abstract][Full Text] [Related]
38. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy.
Kademani D; Koka S; Lacy MQ; Rajkumar SV
Mayo Clin Proc; 2006 Aug; 81(8):1100-3. PubMed ID: 16901034
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonate-related osteonecrosis of the jaw.
Feller L; Wood NH; Khammissa RA; Chikte UM; Bouckaert M; Lemmer J
SADJ; 2011 Feb; 66(1):30-2. PubMed ID: 21510174
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study.
Ripamonti CI; Cislaghi E; Mariani L; Maniezzo M
Oral Oncol; 2011 Mar; 47(3):185-90. PubMed ID: 21310650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
